154 related articles for article (PubMed ID: 18302775)
1. Immunological predictors of CD4+ T cell decline in antiretroviral treatment interruptions.
Seoane E; Resino S; Moreno S; de Quiros JC; Moreno A; Rubio R; Gonzalez-García J; Arribas JR; Pulido F; Muñoz-Fernández MA
BMC Infect Dis; 2008 Feb; 8():20. PubMed ID: 18302775
[TBL] [Abstract][Full Text] [Related]
2. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
3. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
[TBL] [Abstract][Full Text] [Related]
4. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
[TBL] [Abstract][Full Text] [Related]
5. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
6. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
7. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
[TBL] [Abstract][Full Text] [Related]
9. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
[TBL] [Abstract][Full Text] [Related]
10. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
[TBL] [Abstract][Full Text] [Related]
11. Incomplete restoration of Mycobacterium tuberculosis-specific-CD4 T cell responses despite antiretroviral therapy.
Hsu DC; Kerr SJ; Thongpaeng P; Iampornsin T; Pett SL; Zaunders JJ; Avihingsanon A; Ubolyam S; Ananworanich J; Kelleher AD; Cooper DA
J Infect; 2014 Apr; 68(4):344-54. PubMed ID: 24325926
[TBL] [Abstract][Full Text] [Related]
12. Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.
Porter BO; Anthony KB; Shen J; Hahn B; Keh CE; Maldarelli F; Blackwelder WC; Lane HC; Kovacs JA; Davey RT; Sereti I
AIDS; 2009 Jan; 23(2):203-12. PubMed ID: 19098490
[TBL] [Abstract][Full Text] [Related]
13. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial.
Maggiolo F; Ripamonti D; Gregis G; Quinzan G; Callegaro A; Suter F
AIDS; 2004 Feb; 18(3):439-46. PubMed ID: 15090796
[TBL] [Abstract][Full Text] [Related]
14. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
[TBL] [Abstract][Full Text] [Related]
15. Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.
Gerna G; Piccinini G; Genini E; Percivalle E; Zavattoni M; Lilleri D; Testa L; Comolli G; Maserati R; Baldanti F; Maccario R; Monforte AD; Revello MG
J Acquir Immune Defic Syndr; 2001 Dec; 28(4):320-31. PubMed ID: 11707667
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
[TBL] [Abstract][Full Text] [Related]
17. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy.
Kaufmann GR; Bloch M; Finlayson R; Zaunders J; Smith D; Cooper DA
AIDS; 2002 Feb; 16(3):359-67. PubMed ID: 11834947
[TBL] [Abstract][Full Text] [Related]
18. Structured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: effects on leptin and TNF-alpha.
Arjona MM; Pérez-Cano R; Garcia-Juárez R; Martín-Aspas A; del Alamo CF; Girón-González JA
AIDS Res Hum Retroviruses; 2006 Apr; 22(4):307-14. PubMed ID: 16623632
[TBL] [Abstract][Full Text] [Related]
19. It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250 cells/microL.
Skiest DJ; Morrow P; Allen B; McKinsey J; Crosby C; Foster B; Hardy RD
J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1351-7. PubMed ID: 15483464
[TBL] [Abstract][Full Text] [Related]
20. Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.
Darwich L; Esteve A; Ruiz L; Paredes R; Bellido R; Cabrera C; Romeu J; Bofill M; Clotet B; Martinez-Picado J
AIDS Res Hum Retroviruses; 2008 May; 24(5):725-32. PubMed ID: 18462084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
